- Home
- SIBN vs GHRS Comparison
SIBN vs GHRS Comparison
Compare SIBN & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SIBN
- GHRS
- Stock Information
- Founded
- SIBN 2008
- GHRS 2018
- Country
- SIBN United States
- GHRS Ireland
- Employees
- SIBN N/A
- GHRS N/A
- Industry
- SIBN Medical/Dental Instruments
- GHRS Biotechnology: Pharmaceutical Preparations
- Sector
- SIBN Health Care
- GHRS Health Care
- Exchange
- SIBN Nasdaq
- GHRS Nasdaq
- Market Cap
- SIBN 733.0M
- GHRS 753.0M
- IPO Year
- SIBN 2018
- GHRS 2021
- Fundamental
- Price
- SIBN $15.46
- GHRS $12.79
- Analyst Decision
- SIBN Strong Buy
- GHRS Strong Buy
- Analyst Count
- SIBN 5
- GHRS 8
- Target Price
- SIBN $24.40
- GHRS $30.63
- AVG Volume (30 Days)
- SIBN 483.1K
- GHRS 427.1K
- Earning Date
- SIBN 08-04-2025
- GHRS 08-07-2025
- Dividend Yield
- SIBN N/A
- GHRS N/A
- EPS Growth
- SIBN N/A
- GHRS N/A
- EPS
- SIBN N/A
- GHRS N/A
- Revenue
- SIBN $185,262,000.00
- GHRS N/A
- Revenue This Year
- SIBN $19.48
- GHRS N/A
- Revenue Next Year
- SIBN $16.86
- GHRS N/A
- P/E Ratio
- SIBN N/A
- GHRS N/A
- Revenue Growth
- SIBN 22.93
- GHRS N/A
- 52 Week Low
- SIBN $11.70
- GHRS $6.00
- 52 Week High
- SIBN $20.05
- GHRS $20.50
- Technical
- Relative Strength Index (RSI)
- SIBN 39.00
- GHRS 44.21
- Support Level
- SIBN $15.20
- GHRS $11.32
- Resistance Level
- SIBN $16.12
- GHRS $13.16
- Average True Range (ATR)
- SIBN 0.93
- GHRS 0.88
- MACD
- SIBN -0.15
- GHRS -0.16
- Stochastic Oscillator
- SIBN 10.84
- GHRS 37.12
About SIBN SI-BONE Inc.
SI-BONE Inc is a medical device company, that develops and commercializes a proprietary minimally invasive surgical implant system in the United States and Internationally. Its products include a series of patented titanium implants and the instruments used to implant them, as well as implantable bone products such as iFuse-3D, iFuse-TORQ and iFuse Bedrock Granite which have applications across sacroiliac joint dysfunction and fusion, adult spinal deformity and degeneration, and pelvic trauma.
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.